
COVID-19 (2019 nCo-V)


David Jay Weber, M.D., M.P.H., FSHEA, FIDSA, FRSM (London) Professor of Medicine, Pediatrics, Epidemiology Associate Chief Medical Officer, UNC Hospitals Medical Director, Hospital Epidemiology University of North Carolina at Chapel Hill

Disclosures: Consultant to PDI, Germitec, Lumagenics, Pfizer; Past Consultant, Merck

CORONAVIRUSES

- Single-stranded, linear, positive-sense RNA, enveloped virus, 120-160 nm
- Reservoirs: Humans, multiple animal species, bats
- Epidemiology: Worldwide; winter and spring in temperate climate
- Syndromes
 - Common colds: Common cause of upper respiratory tract infections
 - Lower tract infections (pneumonia) in immunocompromised individuals and older adults
 - Gastroenteritis
 - Endemic coronaviruses: 229E, HKU1, NL63, OC43
 - Epidemic coronaviruses: SARS, MERS, COVID-19 (nCo-V-19)






UPDATE: COVID-19 INFECTION


- Transmission: Droplet/contact; also likely, indirect contact
- Incubation period: Median, 5 days; mean, 7 days; range, 2-14 days (possible outliers up to 27 days)
- Experience in China
 - Majority of cases arise from close contacts of symptomatic cases; 1-5% of 38,000 close contacts developed COVID-19
 - Transmission is driven by family-clusters (i.e. 75-85% of clusters)
- At diagnosis: ~80% are mild/moderate; ~15% severe; ~5% critical
- Progression: ~10-15% of mild/moderate cases become severe, and ~15-20% of severe become critical
- Mortality: 1%-3%; case fatality rate (if hospitalized, ~15%)
 - Risk of dying related to age: 0-39, 0.2%; 40-49, 0; 50-59, 1.3%; 60-69, 3.7%; 70-79, 8.3%; ≥80, 16.7%
 - Higher risk of dying in persons with underlying diseases
- Treatment: Supportive (no vaccine and no specific drug therapy available)

COVID-19: EPIDEMIOLOGY, COMMENTS

- Cases: Global: >215,500 (~9,000 deaths), >140 countries with cases
 - China has gone 24 hours without community transmission; Outside China: Italy, >35,000 (~3,000 deaths); Spain,>13,500 (~600), France, >9,000
 - US: >8,300 (~150 deaths); NC, 97 cases (0 deaths) 23 counties reporting cases; doubling time every 2-3 days
- Comments
 - NC now has community transmission
 - Major limitations on our COVID-19 response: Critically shortages of PPE and limitations on COVID-19 test material



CORONAVIRUS TIMELINE IN NORTH CAROLINA



SYMPTOMS of nCo-V

- Uncomplicated upper respiratory infection
 - Fever, cough, sore throat, nasal congestion
 - Malaise, headache, muscle aches
 - Shortness of breath
- Most patients have reportedly had mild to moderate respiratory illness
- Older and immunocompromised patients may present with atypical symptoms (e.g., no fever)
- Complications for infection
 - Mild to severe pneumonia
 - Acute Respiratory Distress Syndrome
 - Sepsis
 - Septic shock


WHO. https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. 24 January; Rothan HA, Byrareddy SN. J Autoimmunity (In press)

Systemic Disorders **Respiratory Disorders** Fever, Cough, Fatigue, Rhinorrhoea, Sputum Production, Sneezing, Sore Throat Headache Pneumonia Haemoptysis, Acute Cardiac Injury Ground-glass Opacities Hypoxemia RNAaemia, Acute Dyspnoea, Syndrome Lymphopenia Diarrhoea

Respiratory Distress


COVID-19, TIME LINE OF INFECTION COURSE

Symptoms begin days after exposure (range 2-14)



Li Q, et al. N Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa2001316 Chan JF, et al. Lancet. 2020 Feb 15;395(10223):514-523 Guan WJ, et al. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032 **Huang C, et al. Lancet. 2020 Feb 15;395(10223):497-506**

LIKELY TRANSMISSION ROUTES FOR nCo-V




Understanding the epidemiology of COVID-19 allows one to safely manage patients and informs public health on necessary control measures

Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. J Hosp Infect 2016;92:235-50

KEYS TO COVID-19 MITIGATION: SOCIAL DISTANCING AND DIAGNOSTIC TESTING

SOCIAL DISTANCING FLATTENS THE CURVE!!



MITIGATION STRATEGIES

- Public health interventions
 - Quarantine: Separates and restricts persons exposed to an infectious disease
 - Isolation: Separates and restricts persons who have an infectious disease
 - Case finding: Used by Public Health Departments to locate persons exposed to a known case
 - All of above are dependent on have availability of access to a rapid, sensitive and specific diagnosis test
- Social distancing
 - Must be maintained for 2-3 incubation periods after community acquisition has ceased


https://www.vox.com/2020/3/10/21171481/coronavirus-us-cases-quarantine-cancellation

Effects of social distancing on 1918 flu deaths



Graphic from Washington Post: https://www.washingtonpost.com/health/2020/03/10/social-distancing-coronavirus/ Data from: Hatchett RJ, Mecher CE, Lipsitch M. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7582-7


PROJECTING THE FUTURE OF THE COVID PANDEMIC



* As of 4 July 2003, 251 probable cases of SARS were reported from Canada. This graph does not include one additional case of SARS for whom no date of onset was available. Between 4 and 10 July 2003, 2 probable cases were discarded and one additional probable case was reported. As of 10 July 2003, a total of 250 probable cases of SARS were reported. Source: Health Canada

The 1918 Pandemic

The influenza pandemic of 1918 spread across Europe, Asia and North America in three distinct but uneven waves, and was fatal for about 2 percent of those who caught it. Global data is incomplete, but death rates in Britain hint at the severity of the three waves.



HOPE FOR THE BEST, BUT PREPARE FOR THE WORST (Benjamin Disraeli)









Social distancing, Italy



Italian hospital